Combination CurQD and Vedolizumab in Ulcerative Colitis

Part of paid clinical trials in New York, New York.

Sponsor
Ryan C Ungaro
Study ID
NCT07665294
Phase
PHASE4
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • CurQD — DRUG
    Capsule doses 235mg - 385mg curcumin/150mg-300mg QingDai
  • Placebo — DRUG
    Matching capsules
  • Vedolizumab — DRUG
    as prescribed by participant's provider as part of routine clinical care

Study Details

The purpose of this research study is to test the efficacy and safety of the study intervention, CurQD or placebo (non-active pill), in combination with vedolizumab prescribed as standard of care for patients with ulcerative colitis (UC)..

Key Dates

Start date
Jun 24, 2026
Status verified
Jun 2026
Primary completion
Jun 23, 2027
Completion
Jun 23, 2027

Study Design

Enrollment
160 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: CurQD
    CurQD in 1-2 oral capsules twice a day, increasing doses up to 30 weeks. Dose ranging from 470-1540mg curcumin and 300mg-600mg QingDai
  • Placebo Comparator: Placebo
    Placebo comparator in same dosing frequency

Primary Outcome Measure

Number of participants with clinical remission [ Time Frame: Week 14 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10029-

Find similar trials in New York, NY

By condition
Ulcerative colitis
By specialty
GastroenterologyInflammatory bowel diseaseAutoimmune disease
By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies